Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|September 4, 2026

Accelerating and Streamlining Microbial Process Development With a Novel Technology (Sept 2026)

This executive summary examines how FUJIFILM Biotechnologies' ShunzymeX™ platform addresses the purification challenges that make microbial expression systems slower and less predictable than monoclonal antibody workflows. Andrei Soliakov, PhD, a principal technical project lead of process development at FUJIFILM Biotechnologies, details the engineering of a scarless protease developed in partnership with the University of Edinburgh, along with proof-of-concept results across four structurally diverse model proteins. Readers will see how a standardized downstream workflow shortens the path from expression strain to GMP manufacturing.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.